The second-generation antidepressants are a class of antidepressants characterized primarily by the era of their introduction, approximately coinciding with the 1970s and 1980s, rather than by their chemical structure or by their pharmacological effect. As a consequence, there is some controversy over which treatments actually belong in this class.

The term "third generation antidepressant" is sometimes used to refer to newer antidepressants,^[1] from the 1990s and 2000s, often selective serotonin reuptake inhibitors (SSRIs) such as; fluoxetine (Prozac), paroxetine (Paxil) and sertraline (Zoloft), as well as some non-SSRI antidepressants such as mirtazapine, nefazodone, venlafaxine, duloxetine and reboxetine. However, this usage is not universal.

Examples[edit]

This list is not exhaustive, and different sources vary upon which items should be considered second-generation.

• Amineptine
• Amoxapine
• Bupropion
• Iprindole
• Maprotiline
• Medifoxamine
• Mianserin
• Nomifensine
• Tianeptine
• Trazodone
• Venlafaxine
• Viloxazine

See also[edit]

• Atypical antidepressant
• Development and discovery of SSRI drugs
• Pharmacology of antidepressants
• Tricyclic antidepressant
• Tetracyclic antidepressant
• Serotonin–norepinephrine reuptake inhibitor
• Serotonin antagonist and reuptake inhibitor
• Noradrenergic and specific serotonergic antidepressant

References[edit]

External links[edit]

• Second-Generation+Antidepressive+Agents at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
• Diagrams at toxlab.co.uk
• Overview at sagepub.com
• Overview at psyweb.com
• Overview at sciencedaily.com
• Overview at sabryabdelfattah.tripod.com